We are developing innovative therapies to address patients’ unmet needs in Major Depressive Disorder, Schizophrenia and Bipolar Depression.
Our lead drug candidate (CLE-100) is currently being tested in Phase 2 multicenter studies in the United States.
Our lead preclinical candidate (CLE-905) has recently completed IND enabling activities, with First-In-Human Phase 1 study expected to start in the coming months.
Our multidisciplinary team brings years of experience in the Pharmaceutical and Biotech industries and encompasses end-to-end drug development expertise, from early stage to advanced clinical stages, and regulatory approvals.
Individually and as a team, we are excited every day to use our expertise to innovate, integrate, apply, and develop new and effective solutions for people affected by mental health disorders.
Learn MoreWe are a multi-asset company with a rich and growing pipeline, from preclinical to Phase 2 development stages.
Developing a new treatment paradigm for patients suffering from Major Depressive Disorder
Developing a potent M1/M4 preferential muscarinic agonist for Schizophrenia
Developing a novel NMDA antagonist for Major Depressive Disorder and Bipolar Depression
